DaVita (DVA)
(Delayed Data from NYSE)
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
Zacks News
QuidelOrtho's (QDEL) Latest FDA Nod to Boost Diagnostic Testing
by Zacks Equity Research
QuidelOrtho's (QDEL) receipt of the FDA's latest approval is likely to improve clinical care, provide cost savings and deliver sample-to-result molecular testing across all laboratory settings.
The Zacks Analyst Blog Highlights Otter Tail, Rollins, DaVita and NetEase
by Zacks Equity Research
Otter Tail, Rollins, DaVita and NetEase are included in this Analyst Blog.
Veeva Systems (VEEV) Vault Quality Offerings Adopted by Recipharm
by Zacks Equity Research
Veeva Systems' (VEEV) Vault Quality Suite applications are expected to aid Recipharm in boosting its operational efficiencies.
3 Reasons to Add HealthEquity (HQY) Stock to Your Portfolio
by Zacks Equity Research
HealthEquity's (HQY) strength in HSA raises optimism about the stock.
Santa Claus Rally Sets In: 4 Stocks From Top Sectors to Play
by Sanghamitra Saha
Tap top-ranked Otter Tail (OTTR), Rollins (ROL), DaVita (DVA) and NetEase (NTES) -- that come from top-ranked sectors too -- should realize the ongoing Fed-induced Santa Claus rally in 2023.
Best Growth Stocks to Buy for December 20th
by Zacks Equity Research
MPTI, LZ and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 20, 2023.
Masimo's (MASI) Stork Baby Monitoring System Approved by FDA
by Zacks Equity Research
The latest FDA clearance of Masimo's (MASI) Stork smart home baby monitoring system is likely to provide a continuous and accurate view of babies' health data.
Here's Why You Should Retain QuidelOrtho (QDEL) Stock for Now
by Zacks Equity Research
QuidelOrtho's (QDEL) strong product portfolio raises optimism about the stock.
Glaukos (GKOS) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Ensign Group (ENSG) Sanctions 4% Quarterly Dividend Hike
by Zacks Equity Research
Ensign Group (ENSG) announces a dividend hike, underlining a strong financial position and continued focus on deploying capital to shareholders.
The Zacks Analyst Blog Highlights Everest Group, Comcast, 3M, Molson Coors Beverage and DaVita
by Zacks Equity Research
Everest Group, Comcast, 3M, Molson Coors Beverage and DaVita are included in this Analyst Blog.
Best Growth Stocks to Buy for December 18th
by Zacks Equity Research
DVA, EAT and EG made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 18, 2023.
Here's Why You Should Retain Catalent (CTLT) Stock for Now
by Zacks Equity Research
Catalent's (CTLT) products and services portfolio and technology foundation raise optimism about the stock.
5 Undervalued S&P 500 Stocks to Buy for 2024
by Sweta Killa
Investors seeking to tap the bullish momentum in the S&P 500 should invest in undervalued stocks like Everest Group (EG), Comcast (CMCSA), 3M Company (MMM), Molson Coors (TAP) and DaVita (DVA).
5 Top Growth Stocks to Make the Most of Santa Claus Rally
by Nalak Das
We have narrowed our search to five growth stocks that have solid upside left for the rest of 2023. These are: DOCU, DUOL, DVA, VRT, PLTR.
Boston Scientific (BSX) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Boston Scientific's (BSX) impressive market share gain in the MedSurg segment.
Integer Holdings (ITGR) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Integer Holdings' (ITGR) solid foothold in the broader MedTech space.
Masimo's (MASI) ORi Favored by Study for PaO2 Information
by Zacks Equity Research
Masimo's (MASI) latest study indicates that ORi can be a valuable tool to provide information on arterial oxygenation even during OLV.
Here's Why You Should Retain Surmodics (SRDX) Stock for Now
by Zacks Equity Research
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
Are Medical Stocks Lagging Cardinal Health (CAH) This Year?
by Zacks Equity Research
Here is how Cardinal Health (CAH) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
Best Growth Stocks to Buy for December 12th
by Zacks Equity Research
GFF, DVA and EG made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 12, 2023.
The Zacks Analyst Blog Highlights Everest Group, Comcast, 3M, Molson Coors Beverage and DaVita
by Zacks Equity Research
Everest Group, Comcast, 3M, Molson Coors Beverage and DaVita are part of the Zacks top Analyst Blog.
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
5 Undervalued Stocks in the S&P 500 ETF to Buy for 2024
by Sweta Killa
Many stocks in the S&P 500 ETF may be undervalued and have the potential to rise toward their peak values.
Why You Should Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.